These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18511800)

  • 1. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.
    Cooper A; O'Flynn N;
    BMJ; 2008 May; 336(7655):1246-8. PubMed ID: 18511800
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease.
    Cappuccio FP
    BMJ; 2008 May; 336(7655):1248-9. PubMed ID: 18511801
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.
    Rabar S; Harker M; O'Flynn N; Wierzbicki AS;
    BMJ; 2014 Jul; 349():g4356. PubMed ID: 25035388
    [No Abstract]   [Full Text] [Related]  

  • 4. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 5. Implications of LDL subclass B in patients at cardiovascular risk.
    Moredich C; Kark D; Keresztes P
    Nurse Pract; 2005 Jul; 30(7):16-8, 23, 26, passim; quiz 29-31. PubMed ID: 16021026
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiologists like statins-more than patients do.
    Mitka M
    JAMA; 2001 Dec; 286(22):2799-800. PubMed ID: 11735736
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of dyslipidemia in 2014: European versus American guidelines].
    Radermecker RP
    Rev Med Suisse; 2014 Aug; 10(439):1534-7. PubMed ID: 25272669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 10. [New European and American guidelines on the management of blood cholesterol : similarities and differences].
    Butty A; Rodondi N; Nanchen D
    Rev Med Suisse; 2020 Mar; 16(684):438-443. PubMed ID: 32134222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Cholesterol Guidelines Personalize Risk and Add Treatments.
    Abbasi J
    JAMA; 2019 Feb; 321(8):731-732. PubMed ID: 30725107
    [No Abstract]   [Full Text] [Related]  

  • 12. Statins: a brief summary.
    Pfeffer MA
    Clin Cardiol; 2001; 24(7 Suppl):II-18. PubMed ID: 11444650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin therapy: when to think twice.
    Wahawisan J; Tovar JM; Granberry MC
    J Fam Pract; 2013 Dec; 62(12):726-32. PubMed ID: 24340334
    [No Abstract]   [Full Text] [Related]  

  • 14. Mass treatment with statins.
    Goldacre B; Smeeth L
    BMJ; 2014 Jul; 349():g4745. PubMed ID: 25056140
    [No Abstract]   [Full Text] [Related]  

  • 15. The application of evidence-based principles of care in older persons (issue 2): management of lipid disorders.
    Zarowitz BJ; Aronow WS; Hollenack K; O'Shea T
    J Am Med Dir Assoc; 2006 Mar; 7(3):173-9. PubMed ID: 16503311
    [No Abstract]   [Full Text] [Related]  

  • 16. [The utility of antilipemic agents in the area of secondary prevention].
    Weizet A
    Pharm Unserer Zeit; 2006; 35(2):172. PubMed ID: 16583572
    [No Abstract]   [Full Text] [Related]  

  • 17. Why do statins reduce cardiovascular disease more than other lipid modulating therapies?
    Schooling CM; Au Yeung SL; Leung GM
    Eur J Clin Invest; 2014 Nov; 44(11):1135-40. PubMed ID: 25252212
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipid-lowering therapy in low-risk patients.
    Pearson TA
    JAMA; 1998 May; 279(20):1659-61. PubMed ID: 9613918
    [No Abstract]   [Full Text] [Related]  

  • 19. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.
    Tonkin A; Barter P; Best J; Boyden A; Furler J; Hossack K; Sullivan D; Thompson P; Vale M; Cooper C; Robinson M; Clune E; ;
    Heart Lung Circ; 2005 Dec; 14(4):275-91. PubMed ID: 16361000
    [No Abstract]   [Full Text] [Related]  

  • 20. Statins in liver disease: not only prevention of cardiovascular events.
    Magan-Fernandez A; Rizzo M; Montalto G; Marchesini G
    Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):743-744. PubMed ID: 29768950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.